Clavel F - Search Results

1

Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, Grant RM, Clavel F, McCune JM. Stoddart CA, et al. Among authors: clavel f. Nat Med. 2001 Jun;7(6):712-8. doi: 10.1038/89090. Nat Med. 2001. PMID: 11385509

2

Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues.

Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA. Penn ML, et al. Among authors: clavel f. AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):517-23. doi: 10.1089/08892220151126580. AIDS Res Hum Retroviruses. 2001. PMID: 11350665

3

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.

Mammano F, Petit C, Clavel F. Mammano F, et al. Among authors: clavel f. J Virol. 1998 Sep;72(9):7632-7. doi: 10.1128/JVI.72.9.7632-7637.1998. J Virol. 1998. PMID: 9696866 Free PMC article.

4

Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity.

de la Carrière LC, Paulous S, Clavel F, Mammano F. de la Carrière LC, et al. Among authors: clavel f. J Virol. 1999 Apr;73(4):3455-9. doi: 10.1128/JVI.73.4.3455-3459.1999. J Virol. 1999. PMID: 10074202 Free PMC article.

5

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Zennou V, et al. Among authors: clavel f. J Virol. 1998 Apr;72(4):3300-6. doi: 10.1128/JVI.72.4.3300-3306.1998. J Virol. 1998. PMID: 9525657 Free PMC article.

6

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Mammano F, Trouplin V, Zennou V, Clavel F. Mammano F, et al. Among authors: clavel f. J Virol. 2000 Sep;74(18):8524-31. doi: 10.1128/jvi.74.18.8524-8531.2000. J Virol. 2000. PMID: 10954553 Free PMC article.

7

HIV drug resistance and viral fitness.

Clavel F, Race E, Mammano F. Clavel F, et al. Adv Pharmacol. 2000;49:41-66. doi: 10.1016/s1054-3589(00)49023-x. Adv Pharmacol. 2000. PMID: 11013760 Review. No abstract available.

8

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vézinet F, Clavel F. Hance AJ, et al. Among authors: clavel f. J Virol. 2001 Jul;75(14):6410-7. doi: 10.1128/JVI.75.14.6410-6417.2001. J Virol. 2001. PMID: 11413308 Free PMC article.

9

Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F. Trouplin V, et al. Among authors: clavel f. J Virol. 2001 Jan;75(1):251-9. doi: 10.1128/JVI.75.1.251-259.2001. J Virol. 2001. PMID: 11119595 Free PMC article.

10

Transmission of antiretroviral-drug-resistant HIV-1 variants.

Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Yerly S, et al. Among authors: clavel f. Lancet. 1999 Aug 28;354(9180):729-33. doi: 10.1016/S0140-6736(98)12262-6. Lancet. 1999. PMID: 10475184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters